News

Deal Announcements

Atox Bio Nets $23 Million Venture Capital Investment

Friday, July 25, 2014 5:30:00 AM PDT | VentureDeal
   Ness Zion, Israel  --  Biotechnology company Atox Bio has received $23 million in new venture capital and strategic investment.

Atox is developing novel immune modulators for the treatment of patients in critical care situations.

SR One led the round, which included other undisclosed investors.

The company said it will initiate a late stage clinical study of its AB103 candidate for the treatment of necrotizing soft tissue infections.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1